![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00636259 |
This study provides compassionate use of bicalutamide (Casodex) at a 150-mg dose for subjects with prostate cancer prior to it becoming commercially available. The patient will receive bicalutamide 150-mg as long as the physician feels that the subject is benefiting from this therapy and safety information is provided regularly to AstraZeneca. Treatment will be discontinued after bicalutamide 150-mg becomes commercially available.
Condition | Intervention |
---|---|
Adenocarcinoma of the Prostate |
Drug: Bicalutamide (Casodex) |
Study Type: | Expanded Access |
Official Title: | A Compassionate Use Trial With Bicalutamide (Casodex) 150-mg for Subjects With Prostate Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 7054US/0014, D6874L00006 |
Study First Received: | March 7, 2008 |
Last Updated: | June 10, 2008 |
ClinicalTrials.gov Identifier: | NCT00636259 |
Health Authority: | United States: Food and Drug Administration |
Prostate cancer Casodex |
Prostatic Diseases Genital Neoplasms, Male Bicalutamide Urogenital Neoplasms Genital Diseases, Male |
Adenocarcinoma Prostatic Neoplasms Neoplasms, Glandular and Epithelial Carcinoma |
Androgen Antagonists Neoplasms Neoplasms by Site Neoplasms by Histologic Type Antineoplastic Agents |
Therapeutic Uses Hormone Antagonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Pharmacologic Actions |